- Proceeds intended for general corporate purposes, including working capital, capex, acquisitions or the repayment, redemption or refinancing of a portion of its debt
- PKD down 6.4% post-mkt (vol. 15k)
After Hours Summary: WMGI +5%, DEPO +5%, RRGB +3%, FSLR +2% following earnings/guidance, NVDQ +25% continued strength following Cigna coverage news... SREV -25%, TXRH -10%, WLL -4.2% following earnings/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: LNTH +7% (also the company and GE Healthcare sign a a term sheet relating to the continued Phase III development and worldwide commercialization of flurpiridaz F18), WMGI +5.4%, DEPO +4.6%, DL +4.3%, XPO +3.7%, SRT +3.4%, RRGB +3.3%, HCLP +3.2% (light volume), VMI +2.2%, EXR +2% (ticking higher), FSLR +1.8% (also secures syndicated financing arranged by Mizuho Bank for utility-scale solar project in Japan), UVE +1.7%, LZB +1.4%, WCN +1.1%
Companies trading higher in after hours in reaction to news: NVDQ +25.3% (continued strength after confirming Cigna now covers Dermacell for breast reconstruction surgery and Dermacell AWM for diabetic foot ulcers), TRCO +3% (Starboard Value discloses 6.6% active stake)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: SREV -24.8%, TXRH -10.1%, FUEL -9.8%, DAC -7.4% (ticking lower), WLL -4.2%, PZZA -3.5%, FE -2.9%, KAR -2.5%, NEM -2.1% (also reports gold reserves of 68.5 mln oz for 2016 vs 71.1 mln oz in 2015; provides FY17 capex guidance), SAND -1.7% (light volume), NFX -1.2%
Companies trading lower in after hours in reaction to news: PKD -10.6% (commences 12 mln common stock offering and $50 mln public offering of Series A Mandatory Convertible Preferred Stock), GBT -10% (to sell $75 mln in shares of its common stock in a registered underwritten public offering), AGEN -6.2% (discloses that the Alliance for Clinical Trials in Oncology's Data and Safety Monitoring Board interim analysis for futility of the Phase II trial of Prophage G-200 vaccine in combination with bevacizumab suggested that the trial is unlikely to demonstrate that the vaccine will lead to a better survival than bevacizumab as a monotherapy), TLLP -2.5% (commences 5 mln common units offering), YUM -2% (following block trade pricing), CUZ -1.5% (commences public offering of 63,571,336 shares of its common stock - includes 25 mln shares offered by the company)
- Post-earnings gainers: LNTH +7%, DEPO +4.6%, TEX +2.7%,HCLP +2.6%, XPO +2.3%, FSLR +1.5%
- Post-earnings losers: FUEL -13.7%, SREV -12.9%, TXRH -6.6%, ENTL -2.8%, NYMT -2.3%, WLL -2.3%
- Reports Q4 (Dec) earnings of $0.25 per share, excluding non-recurring items, $0.06 worse than the Capital IQ Consensus of $0.31; revenues rose 23.2% year/year to $1.79 bln vs the $1.75 bln Capital IQ Consensus.
-
Outlook:
- Investments to explore and develop promising expansions and to address previously announced geotechnical issues at Carlin and changes to cost allocation between gold and copper are expected to slightly increase the co's 2017 and 2018 gold cost outlook. Economic assumptions include $1,200 per ounce gold, $2.25 per pound copper, $55 per barrel WTI and $0.75 AUD-USD exchange rate.
- Gold: Attributable gold production outlook is in line with previously published five-year guidance and expected to increase to between 4.9 and 5.4 million ounces in 2017 as full year production at Merian and Long Canyon more than offsets declines at Twin Creeks and Yanacocha. Longer-term production of between 4.5 and 5.0 million ounces is expected with production from Long Canyon and Ahafo partly offsetting declines at maturing assets. Expansion projects at Ahafo, Yanacocha and Twin Creeks represent upside to both production and cost guidance.
- CAS is expected to be between $700 and $750 per ounce in 2017 and between $700 and $800 per ounce in 2018, before any portfolio improvements. Co expects longer term CAS to improve to $650 and $750 per oz. AISC is expected to be between $940 and $1,000 per ounce in 2017 and between $950 and $1,050 per ounce in 2018, excluding further cost and efficiency improvements expected through the Company's ongoing Full Potential program.
- Capex: Total capital is expected to be between $800 and $900 million in 2017, covering the remaining capital for Northwest Exodus and the Tanami Expansion Project. 2017 sustaining capital outlook of between $600 and $700 million represents a 24 percent reduction from previously published guidance due to cost savings and deferrals.
- Copper: Boddington and Phoenix are expected to produce between 40,000 and 60,000 tonnes of copper per year in line with previous guidance excluding Batu Hijau. In 2017, copper costs are expected to be between $1.45 and $1.65 per pound CAS and between $1.85 and $2.05 per pound AISC. Longer term, copper CAS is expected to average between $1.50 and $1.90 per pound and AISC is expected to average between $1.85 and $2.15 per pound, well below previous guidance due to a shift in allocation of costs between copper and gold.